Cingulate grants director options on 20,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cingulate Inc. director Peter J. Werth received a grant of stock options for 20,000 shares of common stock on July 16, 2026. The options have an exercise price of $4.43 per share and expire on July 16, 2036. They vest on the earlier of the one-year anniversary of the grant date or the date of Cingulate Inc.'s 2027 annual meeting of stockholders, leaving Werth with 20,000 stock options held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to Buy) F1 | 20,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders.
Key Figures
Key Terms
Stock Option (right to Buy) financial
exercise price financial
annual meeting of stockholders financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock option grant did Peter J. Werth report for Cingulate (CING)?
What is the exercise price of the new Cingulate (CING) options granted to Peter J. Werth?
When do Peter J. Werth’s Cingulate (CING) stock options vest?
When do the newly granted Cingulate (CING) stock options to Peter J. Werth expire?
How many Cingulate (CING) stock options does Peter J. Werth hold after this grant?
What type of security was granted to Peter J. Werth in Cingulate (CING)?
AI-generated analysis. How Rhea-AI works. Not financial advice.